Skip to main content

Tauriga Sciences, Inc. Appoints Dr. Keith Aqua to Position of Chief Medical Officer

Written by Customer Service on . Posted in Public Companies.


Dr. Aqua has been a Principal Investigator on Over 300 Pharmaceutical Industry-Sponsored Clinical TrialsWellington, FL, July 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has appointed Dr. Keith Aqua (“Dr. Aqua) to the position of Chief Medical Officer (“CMO”) – Effective Immediately.  In this capacity, Dr. Aqua will help the Company progress in its development of its proposed Pharmaceutical grade version of Tauri-Gum™. In addition, he will establish a distribution network for the Company to market its Tauri-Gum™ brand to a variety of physicians and medical practices in Southern Florida. Tauriga’s CEO Seth M. Shaw expressed, “The Company has just secured a very important puzzle piece for its long-term success. Dr. Aqua has a wealth of experience in navigating the drug development process and in addition to that, his network enables the Company to expand its retail product offering – to medical practices. Dr. Aqua will also be assisting in our important and rapidly growing collaboration agreement with Aegea Biotechnologies, Inc.”Commenting on his appointment, Dr. Keith Aqua stated, “After much consideration and due diligence, I have made the decision to join the Tauriga Sciences team in an important capacity.  I am a big believer in the Company’s products and vision and I am confident that I can be of assistance in improving both execution and growth.  I have great confidence that the Company will build a successful future for its shareholders.”Personal Bio – Dr. Keith Aqua:As Chief Medical Officer, Keith A. Aqua, MD brings more than 25 years of industry experience as a private practitioner and certified clinical investigator to Tauriga Sciences. Alongside his clinical research, Dr. Aqua is a board-certified obstetrician/gynecologist with a thriving private practice in West Palm Beach, Florida. He received a B.A. from the University of Pennsylvania and an M.D. from The Ohio State University. After completing his residency at the University of Arizona Health Sciences Center, he co-founded the Institute for Women’s Health and Body, a large single specialty group located in Palm Beach County, Florida. In 2001, he founded Visions Clinical Research and in 2015 the Atlantic Clinical Research Collaborative. He has been a Principal Investigator on over 300 pharmaceutical industry-sponsored clinical trials. He has received numerous teaching awards and has a number of publications and citations related to research in women’s health, dermatology, and family medicine. He is currently a speaker for several pharmaceutical companies and is an adjunct clinical professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University.ABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.comComplementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New YorkDISCLAIMER — Forward-Looking StatementsContact:CONTACT INFORMATION

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.